Spyre Therapeutics Files 10-K/A Amendment for Fiscal Year 2023

TL;DR

<b>Spyre Therapeutics filed an amended 10-K for FY2023, confirming its status as a reporting company and its Nasdaq listing.</b>

AI Summary

Spyre Therapeutics, Inc. (SYRE) filed a Amended Annual Report (10-K/A) with the SEC on March 1, 2024. Spyre Therapeutics, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2023. The company is incorporated in Delaware and its principal executive offices are located in Waltham, MA. Spyre Therapeutics is registered under the SIC code 2834 for Pharmaceutical Preparations. The company's common stock trades on The Nasdaq Stock Market LLC under the symbol SYRE. This filing indicates the company has submitted all required reports for the preceding 12 months and the past 90 days.

Why It Matters

For investors and stakeholders tracking Spyre Therapeutics, Inc., this filing contains several important signals. The filing is an amendment, suggesting potential updates or corrections to the original 10-K filing, which could contain material information for investors. As a pharmaceutical preparations company listed on Nasdaq, this filing is crucial for understanding its regulatory compliance and financial reporting status.

Risk Assessment

Risk Level: low — Spyre Therapeutics, Inc. shows low risk based on this filing. The filing is an amendment to a 10-K, which is a standard annual report. No immediate red flags are present in the provided header information.

Analyst Insight

Review the full amended 10-K filing for any material changes or new disclosures compared to the original filing.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period for the 10-K/A)
• 2024-03-01 — Filing Date (Date the amendment was filed)
• 001-37722 — SEC File Number (Commission file number for the company)

Key Players & Entities

• Spyre Therapeutics, Inc. (company) — Registrant
• SYRE (company) — Trading Symbol
• The Nasdaq Stock Market LLC (company) — Exchange
• Delaware (company) — State of Incorporation
• Waltham, MA (company) — Principal Executive Offices

FAQ

Industry Context

Spyre Therapeutics operates within the Pharmaceutical Preparations industry, focusing on the development and commercialization of drugs.

Regulatory Implications

The company is subject to the reporting requirements of the Securities Exchange Act of 1934, including filing annual reports (10-K) and amendments.

What Investors Should Do

1. Analyze the full amended 10-K for specific financial data and business updates.
2. Verify the reason for the amendment and any newly disclosed material information.
3. Monitor future SEC filings for ongoing compliance and disclosures.

Year-Over-Year Comparison

This is an amended 10-K filing for the fiscal year 2023, indicating updates or corrections to the previously submitted annual report.

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 Par Value Per Share SYRE The Nasdaq St
• $11.2625 — arter), based upon the closing price of $11.2625 of the Registrant's common stock as rep

Filing Documents

• syre-20231231.htm (10-K/A) — 151KB
• ex311_spyre-202312311.htm (EX-31.1) — 4KB
• ex312_spyre-202312311.htm (EX-31.2) — 4KB
• 0001636282-24-000010.txt (&nbsp;) — 392KB
• syre-20231231.xsd (EX-101.SCH) — 3KB
• syre-20231231_lab.xml (EX-101.LAB) — 41KB
• syre-20231231_pre.xml (EX-101.PRE) — 24KB
• syre-20231231_htm.xml (XML) — 5KB

EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

has been amended to include hyperlinks for all Exhibits

Item 15 has been amended to include hyperlinks for all Exhibits. Exhibits Exhibit Number Incorporate by Reference Description of Document Form File No. Date of Filing Exhibit No. Filed Herewith 2.1 Agreement and Plan of Merger, dated June 22, 2023, by and among the Company, Aspen Merger Sub I, Inc., Sequoia Merger Sub II, LLC and Spyre Therapeutics, Inc. S-1/A 333-276251 2/5/2024 2.1 3.1 Amended and Restated Certificate of Incorporation S-1/A 333-276251 2/5/2024 3.1 3.2 Amended and Restated Bylaws S-1/A 333-276251 2/5/2024 3.2 3.3 Certificate of Designations of Series A Non-Voting Convertible Preferred Stock S-1/A 333-276251 2/5/2024 3.3 3.4 Certificate of Designations of Series B Non-Voting Convertible Preferred Stock S-1/A 333-276251 2/5/2024 3.4 4.1 Form of Registration Rights Agreement, by and among the Company and certain purchasers (December 2023 PIPE) S-1/A 333-276251 2/5/2024 4.1 4.2 Form of Common Stock Certificate S-1/A 333-276251 2/5/2024 4.2 4.3 Securities Purchase Agreement, dated December 7, 2023, by and among Spyre Therapeutics, Inc. and each purchaser identified on Annex A thereto S-1/A 333-276251 2/5/2024 4.3 4.4 Form of Registration Rights Agreement, by and among the Company and certain purchasers (June 2023 PIPE) S-1/A 333-276251 2/5/2024 4.4 4.5* Description of the Registrant's securities 4.6 Form of Pre-Funded Warrants 2022 S-1/A 333-276251 2/5/2024 4.5 10.1 Form of Indemnification Agreement S-1/A 333-276251 2/5/2024 10.19 10.2 2015 Equity Incentive Plan and forms of award agreements S-1/A 333-276251 2/5/2024 10.7 10.3 Spyre Therapeutics, Inc. 2016 Equity Incentive Plan, As Amended and Restated Effective November 21, 2023 S-1/A 333-276251 2/5/2024 10.8 10.4* Spyre Therapeutics, Inc. 2016 Employee Stock Purchase Plan, as amended by the First Amendment on January 31, 2024 Exhibit Number Incorporate by Reference Description of Document Form File No. Date of Filing Exhibit No

SIGNATURES

SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: March 1, 2024 SPYRE THERAPEUTICS, INC. By: /s/ Scott Burrows Scott Burrows Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

View Full Filing

View this 10-K/A filing on SEC EDGAR